Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 79 citing articles:

Major depressive disorder
Wolfgang Marx, Brenda W.J.H. Penninx, Marco Solmi, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Closed Access | Times Cited: 225
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 527-543
Open Access | Times Cited: 108
Ketamine treatment for depression: a review
Mani Yavi, Holim Lee, Ioline D. Henter, et al.
Discover Mental Health (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 85
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes
Raymond W. Lam, Sidney H. Kennedy, G. Camelia Adams, et al.
The Canadian Journal of Psychiatry (2024) Vol. 69, Iss. 9, pp. 641-687
Open Access | Times Cited: 55
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders
Felicia Ceban, Joshua D. Rosenblat, Kevin Kratiuk, et al.
CNS Drugs (2021) Vol. 35, Iss. 9, pp. 925-934
Closed Access | Times Cited: 61
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder
Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, et al.
The Canadian Journal of Psychiatry (2022) Vol. 68, Iss. 1, pp. 5-21
Open Access | Times Cited: 42
Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression
August P. M. Lullau, E. Haga, Eivind Haga Ronold, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 38
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Fabrice Jollant, Romain Colle, Thi Mai Loan Nguyen, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 33
Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada
Carson Chrenek, Bryan Duong, Atul Khullar, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 7
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 7
Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs
Qinghua Guo, L. B. Guo, Wang Yong, et al.
Psychiatry Research (2024) Vol. 339, pp. 116018-116018
Closed Access | Times Cited: 6
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing
Jennifer Swainson, Larry J. Klassen, Stefan Brennan, et al.
CNS Drugs (2022) Vol. 36, Iss. 3, pp. 239-251
Open Access | Times Cited: 25
Psychedelics in the treatment of unipolar and bipolar depression
Oliver G. Bosch, Simon Halm, Erich Seifritz
International Journal of Bipolar Disorders (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 19
Blood pressure changes during ketamine infusion for the treatment of depression
Mina Ansari, Brian Pittman, Daniel S. Tylee, et al.
General Hospital Psychiatry (2024) Vol. 90, pp. 62-67
Closed Access | Times Cited: 4
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Maxwell Zachary Price, Richard L. Price
Biomarkers in Neuropsychiatry (2024) Vol. 11, pp. 100104-100104
Open Access | Times Cited: 4
Is there a risk of esketamine misuse in clinical practice?
Carlos Roncero, M. Merizalde Torres, Néstor Szerman, et al.
Therapeutic Advances in Drug Safety (2025) Vol. 16
Open Access
Inside the Journey: A Qualitative Study of Intravenous Ketamine Therapy for Treatment-Resistant Depression in Canada
Jason Perepelkin, Polixeni Hantjidis, Kristopher K. Robison, et al.
Journal of Affective Disorders Reports (2025), pp. 100886-100886
Open Access
Ketamine for mental health - A naturalistic inventory of prescribing practices, safety, and adverse effects
Marta Stuart, Ian Stefanuk, Rebecca Comeau, et al.
PLOS mental health. (2025) Vol. 2, Iss. 4, pp. e0000215-e0000215
Open Access
Rapid treatments for depression: Endocannabinoid system as a therapeutic target
AmirMohammad Sharafi, Sina Pakkhesal, Ali Fakhari, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 137, pp. 104635-104635
Closed Access | Times Cited: 18
Practical pathway for the management of depression in the workplace: a Canadian perspective
Pratap Chokka, Ash Bender, Stefan Brennan, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 9
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen Wen, Wenjing Zhao, Xing Xia, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 242, pp. 173773-173773
Closed Access | Times Cited: 3
Cognitive changes in patients with unipolar TRD treated with IV ketamine: A systematic review
Verónica Grasso, Gilmar Gutiérrez, Najat Alzbeidi, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 135, pp. 111095-111095
Open Access | Times Cited: 3
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
Nicolas Garel, Jessica Drury, Julien Thibault Lévesque, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 8
Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression
Xiaofeng Lan, Chengyu Wang, Fan Zhang, et al.
General Psychiatry (2023) Vol. 36, Iss. 3, pp. e101007-e101007
Open Access | Times Cited: 7
Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry
Piotr Gałecki, Katarzyna Bliźniewska-Kowalska, Wiesław Jerzy Cubała, et al.
Psychiatria Polska (2024) Vol. 58, Iss. 3, pp. 377-401
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top